TABLE 3.
Description of plans used for the control dataset
| Plan number | Tumor site | Dose per fraction (Gy) | Number of beams | Average number of segments per beam | Dose point prescription (MUs/Gy) | MCS score | Average γ‐passing rate c (%) | Number of beams used |
|---|---|---|---|---|---|---|---|---|
| 1 | Breast | 0.082 | 2 | 3 | 93.25 | N.A. b | 99.37 | 2 |
| 2 | Prostate | 0.187 | 6 | 8 | 378.05 | 0.63 | 98.02 | 2 |
| 3 | Prostate | 0.106 | 7 | 10 | 266.64 | 0.51 | 98.97 | 1 |
| 4 | Mediastinum | 0.306 | 7 | 10 | 208.15 | 0.30 | 98.11 | 7 |
| 5 | Brain | 0.187 | 6 | 6 | 206.34 | 0.69 | 97.71 | 6 |
| 6 | H&N a | 0.213 | 5 | 12 | 230.48 | 0.60 | 97.57 | 5 |
| 7 | Lungs | 0.068 | 6 | 8 | 270.57 | 0.58 | 98.17 | 6 |
a
Head and Neck tumor site.
b
Non‐Applicable values of MCS score 49 are caused by a specific case where all MLC leaves of a bank are aligned.
c
The average γ‐passing rate is computed on all beams of the plan with the criteria of 2%‐2mm > 10% Dmax.